Myriad Genetics Inc (MYGN) bonds
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.53−0.01 (-0.18%)
Close on Nov 18, 2026Market cap $528.94MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$120.70M
Long-term debt
Net debt
$5.50M
After $115.20M of cash
Implied interest rate
13.17%
FY2025 interest ÷ average debt
Interest coverage
-36.9×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Notes and loans outstanding
As tagged in Myriad Genetics's 10-Q for the period ended Jul 31, 2025
Myriad Genetics's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn |
|---|---|---|
| ABL Facility | – | $39.60M |
| Credit Agreement | – | $200.00M |
See a number that looks wrong?